Clinical Trials Browser

Phase 3 × liposomal doxorubicin × 90 days × Clear all

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT07060807 2026-04-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

1,000 enrolled

Breast

Breast Neoplasms

NCT07214779 2026-04-16

MAESTRA 2

Phase 3 Recruiting

466 enrolled

Gynecologic

Ovarian Neoplasms

NCT06072781 2026-04-02

RAMP 301

Phase 3 Recruiting

270 enrolled

Gynecologic

Low Grade Serous Ovarian Cancer

NCT06312176 2026-04-02

MK-2870-010

Phase 3 Recruiting

1,200 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT07286266 2026-03-19

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Phase 3 Not yet recruiting

450 enrolled

Gynecologic

Ovarian Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Phase 3 Recruiting

186 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Phase 3 Terminated

358 enrolled

Gynecologic

Ovarian Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

Phase 3 Active not recruiting

340 enrolled

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06619236 2026-03-03

RAINFOL-02

Phase 3 Active not recruiting

530 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05411237 2026-01-23

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

Phase 3 Not yet recruiting

130 enrolled

Sarcoma

AIDS-related Kaposi sarcoma, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

Clinical Trials

FRAmework-01

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

MAESTRA 2

RAMP 301

MK-2870-010

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

KEYNOTE-B49

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

RAINFOL-02

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma